sbrimble.bsky.social
@sbrimble.bsky.social
For fun I created this. Retrieved data from DAPA-CKD on change in eGFR over time in 2 arms. Then looked at other drugs, adjusting for differences in placebo progression rates between trials. Then started at median eGFR for DAPA-CKD. Time to eGFR of 8. Pseudo-science perhaps but interesting
December 1, 2025 at 1:49 AM
For fun I created this. Retrieved data from DAPA-CKD on change in eGFR over time in 2 arms. Then looked at other drugs, adjusting for differences in placebo progression rates between trials. Then started at median eGFR for DAPA-CKD. Time to eGFR of 8. Pseudo-science perhaps but interesting
God I could not disagree more, at least with the sentiment/rationale provided (see below). Might as well have entitled it “Make American Nephrology Great Again”. I should add that is even though I have issues with how heavily industry-conflicted KDIGO can be.
April 16, 2025 at 3:32 PM
God I could not disagree more, at least with the sentiment/rationale provided (see below). Might as well have entitled it “Make American Nephrology Great Again”. I should add that is even though I have issues with how heavily industry-conflicted KDIGO can be.
It’s the Police, man. And I’m old. Old enough to remember this movie…
April 6, 2025 at 9:03 PM
It’s the Police, man. And I’m old. Old enough to remember this movie…
March 11, 2025 at 10:25 PM
February 2, 2025 at 10:40 PM
I don’t know the prevalence of cinacalcet use in our program but suspect similar to what Swap reports in his. Ontario criteria for funding of cinacalcet is below and seems mostly reasonable to me based on my review of the evidence.
January 22, 2025 at 10:37 AM
I don’t know the prevalence of cinacalcet use in our program but suspect similar to what Swap reports in his. Ontario criteria for funding of cinacalcet is below and seems mostly reasonable to me based on my review of the evidence.